Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Frankfurt
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

ZEL:GR

4.140 EUR 0.016 0.38%

As of 03:05:02 ET on 04/27/2015.

Snapshot for Zeltia SA (ZEL)

Open: 4.124 Day's Range: 4.124 - 4.205 Volume: 0
Previous Close: 4.156 52wk Range: 2.270 - 4.240 1-Yr Rtn: +56.29%

Stock Chart for ZEL

No chart data available.
  • ZEL:GR 4.197
  • 1D
  • 1M
  • 1Y
4.156
Interactive ZEL Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for ZEL

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) 44.5161
Relative P/E vs. DAX -
Earnings Per Share (EUR) (ttm) -
Est. EPS (EUR) (12/2015) 0.0930
Est. PEG Ratio -
Market Cap (M EUR) 919.93
Shares Outstanding (M) 222.20
30 Day Average Volume 960
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend (EUR) -
Dividend Ex-Date 07/15/2011
5 Year Dividend Growth -
Next Earnings Announcement 04/29/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for ZEL

  • Revenue
  • Net Income (M/EUR)
  • Profit Margin (%)

Company Profile & Key Executives for ZEL

Zeltia, S.A. is a holding composed of biotechnological and chemical companies. The Company's main activity is developing marine derived anti-cancer drugs and CNS pathologies treatments. Zeltia's other activities include developing diagnosis kits and RNAi technology based therapeutical applications.

Jose Maria Fernandez Sousa-FaroChairmanPedro Francisco Fernandez PuentesVice Chairman
Maria Luisa De Francia CaballeroChief Financial OfficerFernando Mugarza BorqueDir:Communication
More Company Profile & Key Executives for ZEL

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil